Long-term use of hydroxypropyl cellulose ophthalmic insert to relieve symptoms of dry eye in a contact lens wearer: Case-based experience

Eye and Contact Lens

Volumn 37, Issue 1, 2011, Pages 39-44

  Wander, Arden H ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Artificial tears; Contact lenses; Dry eye; Hydroxypropyl cellulose; Keratoconjunctivitis sicca; Lacrisert

Indexed keywords

ANTINUCLEAR ANTIBODY; ARTIFICIAL TEAR; HYDROXYPROPYLCELLULOSE; IMMUNOGLOBULIN G; RHEUMATOID FACTOR;

ADULT; ARTICLE; CASE REPORT; CONTACT LENS; DRUG TOLERABILITY; DRY EYE; FEMALE; HUMAN; KERATOCONJUNCTIVITIS SICCA; LACRIMATION; PRIORITY JOURNAL; SCHIRMER TEST; SJOEGREN SYNDROME; SLIT LAMP; SOFT CONTACT LENS; VISUAL ACUITY;

ADULT; CELLULOSE; CONTACT LENSES; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; DRY EYE SYNDROMES; FEMALE; HUMANS; SJOGREN'S SYNDROME; TREATMENT OUTCOME;

EID: 78650817681     PISSN: 15422321     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICL.0b013e3181f84f92     Document Type: Article

References (40)

1. The definition and classification of dry eye disease: Report of the definition and classification subcommittee of the international dry eye workshop. Ocul Surf 2007;5:75-92.
2. The epidemiology of dry eye disease: Report of the epidemiology subcommittee of the international dry eye workshop. Ocul Surf 2007;5: 93-107.
3. Nelson JD, Helms H, Fiscella R, et al. A new look at dry eye disease and its treatment. Adv Ther 2000;17:84-93.
4. Miljanovic B, Dana R, Sullivan DA, et al. Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol 2007;143:409-415.
5. Pflugfelder SC, Solomon A, Stern ME. The diagnosis and management of dry eye: A twenty-five-year review. Cornea 2000;19:644-649.
6. Friedman NJ. Impact of dry eye disease and treatment on quality of life. Curr Opin Ophthalmol 2010;21:310-316.
7. Tong L, Waduthantri S, Wong TY, et al. Impact of symptomatic dry eye on vision-related daily activities: The Singapore Malay Eye Study. Eye (Lond) 2010;24:1486-1491.
8. Sheppard JD. Guidelines for the treatment of chronic dry eye disease. Manag Care 2003;12(12 Suppl):20-25.
9. Lemp MA. Advances in understanding and managing dry eye disease. Am J Ophthalmol 2008;146:350-356.
10. Schaumberg DA, Sullivan DA, Buring JE, et al. Prevalence of dry eye syndrome among US women. Am J Ophthalmol 2003;136:318-326.
11. Schaumberg DA, Dana R, Buring JE, et al. Prevalence of dry eye disease among US men: Estimates from the physicians' health studies. Arch Ophthalmol 2009;127:763-768.
12. Moss SE, Klein R, Klein BE. Long-term incidence of dry eye in an older population. Optom Vis Sci 2008;85:668-674.
13. Dalzell MD. Dry eye: Prevalence, utilization, and economic implications. Manag Care 2003;12(12 Suppl):9-13.
14. Lemp MA. Management of dry eye disease. Am J Manag Care 2008; 14(3 Suppl):S88-S101.
15. Management and therapy of dry eye disease: Report of the management and therapy subcommittee of the international dry eye workshop. Ocul Surf 2007;5:163-178.
16. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren's syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61: 554-558.
17. Chalmers RL, Begley CG. Dryness symptoms among an unselected clinical population with and without contact lens wear. Cont Lens Anterior Eye 2006; 29:25-30.
18. Begley CG, Caffery B, Nichols KK, et al. Responses of contact lens wearers to a dry eye survey. Optom Vis Sci 2000;77:40-46.
19. Guillon M, Maissa C. Dry eye symptomatology of soft contact lens wearers and nonwearers. Optom Vis Sci 2005;82:829-834.
20. Richdale K, Sinnott LT, Skadahl E, et al. Frequency of and factors associated with contact lens dissatisfaction and discontinuation. Cornea 2007;26: 168-174.
21. Ramamoorthy P, Sinnott LT, Nichols JJ. Treatment, material, care, and patient-related factors in contact lens-related dry eye. Optom Vis Sci 2008;85: 764-772.
22. Guillon M, Maissa C. Contact lens wear affects tear film evaporation. Eye Contact Lens 2008;34:326-330.
23. Nichols KK, Nichols JJ, Mitchell GL. The lack of association between signs and symptoms in patients with dry eye disease. Cornea 2004;23:762-770.
24. Behrens A, Doyle JJ, Stern L, et al. Dysfunctional tear syndrome: A Delphi approach to treatment recommendations. Cornea 2006;25:900-907.
25. Pflugfelder SC. Prevalence, burden, and pharmacoeconomics of dry eye disease. Am J Manag Care 2008;14(3 Suppl):S102-S106.
26. Hirsch JD. Considerations in the pharmacoeconomics of dry eye. Manag Care 2003;12(12 Suppl):33-38.
27. Mertzanis P, Abetz L, Rajagopalan K, et al. The relative burden of dry eye in patients' lives: Comparisons to a U.S. normative sample. Invest Ophthalmol Vis Sci 2005;46:46-50.
28. Lacrisert (hydroxypropyl cellulose ophthalmic insert) [package insert]. Lawrenceville, NJ: Aton Pharma, Inc; 2007.
29. Breslin C, Katz J, Kaufman HE, et al. Slow-release artificial tears. In: Leopold IH, Burns RP, eds. Symposium on Ocular Therapy. New York, NY, John Wiley & Sons, 1977, pp. 77-83.
30. Katz JI, Kaufman HE, Breslin C, et al. Slow-release artificial tears and the treatment of keratitis sicca. Ophthalmology 1978;85:787-793.
31. Laurenzi A. A sustained-release insert for moderate to severe dry eye. Cont Lens Spectr 2008;December.
32. McDonald MB. Versatile approach key in treating moderate to severe dry eye. Ocular Surg News 2008; October 25.
33. Hill JC. Slow-release artificial tear inserts in the treatment of dry eyes in patients with rheumatoid arthritis. Br J Ophthalmol 1989;73:151-154.
34. Trattler WB, Asbell P, Stein J. Punctal plugs/ophthalmic insert can alleviate dry eye. Cataract Refract Surg Today 2009; Apr:62-67.
35. McDonald M, D'Aversa G, Perry HD, et al. Hydroxypropyl cellulose ophthalmic inserts (lacrisert) reduce the signs and symptoms of dry eye syndrome and improve patient quality of life. Trans Am Ophthalmol Soc 2009;107:214-221.
36. Koffler BH, McDonald M, Nelinson DS. Improved signs, symptoms, and quality of life associated with dry eye syndrome: Hydroxypropyl cellulose ophthalmic insert patient registry. Eye Contact Lens 2010;36: 170-176.
37. Luchs JI, Nelinson D, Macy JI, et al. Efficacy of hydroxypropyl cellulose ophthalmic inserts (LACRISERT) in subsets of patients with dry eye syndrome: Findings from a patient registry [published online ahead of print September 15, 2010]. Cornea, doi: 10.1097/ICO.0b013e3181e3f05b.
38. Curwen S, Torkildsen G, Ousler G, III, et al. Effect of Lacrisert on the signs and symptoms of dry eye in contact lens wearers. Poster presented at: The Association for Research in Vision and Ophthalmology (ARVO) 2009 Annual Meeting; May 3-7, 2009; Ft. Lauderdale, FL. Program #4661/Poster #D905.
39. Aton Pharma, Inc. Lacrisert Clinical White Paper [Lacrisert web site]. 2007. Available at: http://www.lacrisert.com/attachments/LacrisertClinicalWhite Paper.pdf. Accessed January 5, 2009.
40. Wander AH, Koffler BH. Extending the duration of tear film protection in dry eye syndrome: Review and retrospective case series study of the hydroxypropyl cellulose ophthalmic insert. Ocul Surf 2009;7:154-162.